The death of adolescent and young adult patients due to sarcoma is a tragedy. In efforts to avoid this, much development of treatment strategies has occurred in the past several years. These include not only technical developments such as molecular targeted therapy, heavy particle radiotherapy, Intensity Modulated Radiation Therapy (IMRT), Tomotherapy, PET-CT, and interventional radiology, but also improvements in the medical systems such as standardization of chemotherapy by the Japan Clinical Oncology Group (JCOG), establishment of the Japanese Society of Medical Oncology, home health care program, rehabilitation for cancer patients, and cancer board. Intense discussion on these new and multimodal approaches is being anticipated at the 47th Annual Musculoskeletal Tumor Meeting of the Japanese Orthopaedic Association (JOA), which will be held July 17-18, 2014 in Osaka, Japan [1] . In preparation for the meeting, several topics are outlined below.
Since the discovery of the double helix structure of DNA, researchers have intently studied the causes of cancer development. Chromosomal translocations, oncogenes, and anti-oncogenes were the main themes in cancer research during the 1960s and through the 1990s. In the orthopaedic field, mainly retinoblastoma genes in osteosarcoma and fusion genes in soft tissue sarcomas were investigated [2] . As molecular biology techniques have progressed, the driver mutation of several cancers revealed abnormalities in tyrosine kinases that work in the signal transduction of cancer cells. Subsequently, inhibitors of the abnormal tyrosine kinases were generated and marketed for medical use, such as imatinib for chronic myelogenous leukemia (CML) and gefitinib for epidermal growth factor receptor (EGFR) mutation-positive lung cancer. These drugs have dramatically changed the prognosis of the patients.
For sarcoma, pazopanib, a multi-targeted tyrosine kinase inhibitor, was marketed for medical use approximately one year ago in Japan. The phase III clinical trial in 72 institutions across 13 countries revealed a median progression-free survival of 4.6 months (95 % CI 3.7-4.8) for pazopanib, compared with 1.6 months (0.9-1.8) for placebo [hazard ratio (HR) 0.31, 95 % CI 0.24-0.40; p \ 0.0001] [3] . Even with only one year's experience of clinical use, there exists a population of super-responders to pazopanib, as observed with gefitinib. Although careful attention to the occurrence of pneumothorax is necessary due to the complete remission of lung metastases in the super-responders, this drug is considered a breakthrough in sarcoma treatment. Further investigations on the driver pathway in individual histology of sarcoma and its synergetic effects with other drugs are expected as issues for future study.
A 30-year history of prosthetic reconstruction of malignant bone tumor has revealed the increasing importance of maintenance surgery for the prosthesis. The design of knee joint mechanisms is changing from a rigid constrained type to a rotating hinge type. However, infection, breakage, and hinge replacement are still the major problems in prosthetic surgery. Orthopaedic oncologic surgeons should be encouraged to generate creative ideas to reduce the need for maintenance surgery.
Instead of the prosthesis, recycled bone may be a good substitute for certain cases. Irradiation, pasteurization, heat treatment, and freezing are used to kill the tumor cells in the autogenous graft of tumor-bearing bone. From the longterm results of our cases of irradiated bone graft, it is important to use recycled bone graft with the awareness of the advantages and disadvantages of the methods. The disadvantages include high rates of complication and reoperation of osteoarticular grafts. The advantages include the preservation of tendon and muscle insertion for better function. We should be aware of the features and should apply this method to qualifying patients with appropriate indications [4, 5] .
Instead of surgery, heavy particle radiotherapy has become the first choice of treatment for large sacral chordoma. Other inoperable sarcomas of the pelvis or spine are also being treated by this method. The high biological effectiveness and Bragg peak present a chance to survive for patients with desperate conditions. However, the bone destruction after this radiation is extremely severe; therefore orthopaedic surgeons need to establish a salvage method for post-radiation deformity of the spine or pelvis. Other stereotactic body radiation therapies, such as Novalis and Tomotherapy, are also useful treatment choices for selected patients. In addition to these available techniques, Boron Neutron Capture Therapy (BNCT) is now under investigation as the next generation radiotherapy. It utilizes the difference in 10 B-concentration between the tumor and normal tissue under irradiation with thermal neutrons. Soft tissue sarcomas are reported as promising targets for future BNCT research. In addition to these improvements in irradiation techniques, interventional radiology, such as trans-catheter arterial embolization (TAE) using permanent embolic material, radiofrequency ablation (RFA), and kyphoplasty are also undergoing developments. Application of these new techniques in radiology will be expected to give new clinical benefits to the patients.
Despite the improvement of the above-mentioned treatment strategies, pathological fractures and paraplegia from spinal metastasis remain as major problems. There are neither standardized guidelines nor clinical trials to aid in the decision of treatment procedure for these conditions. Moreover, since most orthopaedic surgeons are not familiar with malignant diseases because of the rarity of malignancy in the bone and soft tissues, it is very difficult to select the appropriate operative procedure for these conditions. Apparently, more studies in this field are urgently required. Aside from surgical intervention, PET-CT, and bone modifying agent (BMA), molecular targeted drugs for cancer have appeared with remarkable influence and impact on the treatment strategy of bone metastasis. PET-CT can easily detect the tumor spread. BMA, such as zoledronic acid and denosumab, decreases the skeletal related event. The super-responders to molecular targeted therapy have changed our concepts on treatment of bone metastasis in that they usually do not need operation. In addition, a promising procedure, MRI-guided focused ultrasound (FUS), has received food and drug administration approval for pain relief of bone metastasis in the United States. Now is the time for orthopaedic oncologists to play a part in the establishment of practical guidelines, medical care systems, and new clinical trials for bone metastasis.
Enthusiasm for the cooperation of molecular biology, pharmacology, surgery, radiology, and medical systems will be the key for better prognosis of patients in the field of orthopaedic oncology. Hopefully, attendees of the upcoming 47th Annual Musculoskeletal Tumor Meeting of the JOA will discuss these issues heartily in order to be comrades against sarcoma.
